618-83-7

Basic information

• Product Name: 5-Hydroxyisophthalic acid
• Synonyms: OHIPA;5-HYDROXYBENZENE-1,3-DICARBOXYLIC ACID;5-HYDROXYISOPHTHALIC ACID;5-HYDROXYISOPTHALIC ACID;5-HIPA;5-HYDROXY-1,3-BENZENEDICARBOXYLIC ACID;HYDROXYISOPHTHALIC-5 ACID;HYDROXYISOPHTHALIC ACID, 5-
• CAS NO: 618-83-7
• Molecular Formula: C₈H₆O₅
• Molecular Weight: 182.13
• EINECS: 210-565-7
• Product Categories: Benzene derivatives;Phthalic Acids, Esters and Derivatives;Organic acids;Building Blocks for Dendrimers;Functional Materials;C8;Carbonyl Compounds;Carboxylic Acids
• Mol File: 618-83-7.mol
• Article Data: 8

Chemical Properties

• Melting Point: 298-302 °C(lit.)
• Boiling Point: 235.5°C (rough estimate)
• Flash Point: 280.5 °C
• Appearance: White to slightly yellow/Powder
• Density: 1.3293 (rough estimate)
• Vapor Pressure: 1.65E-11mmHg at 25°C
• Refractive Index: 1.4330 (estimate)
• Storage Temp.: Store below +30°C.
• Solubility: 0.6g/l
• PKA: 3.41±0.10(Predicted)
• Water Solubility: 0.6g/L(15 oC)
• BRN: 2693561
• CAS DataBase Reference: 5-Hydroxyisophthalic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Hydroxyisophthalic acid(618-83-7)
• EPA Substance Registry System: 5-Hydroxyisophthalic acid(618-83-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-37/39-24/25-36
• WGK Germany: 2
• RTECS: CZ4280000
• TSCA: Yes
• Hazardous Substances Data: 618-83-7(Hazardous Substances Data)

Usage

Chemical Properties

white to slightly yellow powder

General Description

The hydrothermal reaction of 5-hydroxyisophthalic acid, Co(II)/Cu(II) and dipyridophenazine, that forms two 3D chiral coordination polymers, was studied.

InChI:InChI=1/C8H6O5/c9-6-2-4(7(10)11)1-5(3-6)8(12)13/h1-3,9H,(H,10,11)(H,12,13)/p-2

Upstream product

• 855397-05-6 6-bromo-3-methoxy-5-oxo-cyclohepta-1,3,6-trienecarboxylic acid 
• 23351-91-9 5-bromoisophthalic acid 
• 121-91-5 isophthalic acid 
• 13036-02-7 Dimethyl 5-hydroxyisophthalate 
• 4440-39-5 stipitatic acid 
• 82-12-2 rufigallol 
• 56961-33-2 3-Chloro-5-Methylbenzoic Acid 
• 22326-31-4 5-sulfoisophthalic acid 
• 481-74-3 Chrysophanol 
• 855396-95-1 6-methoxy-3-oxo-cyclohepta-1,4,6-trienecarboxylic acid 
• 99-31-0 5-aminoisophthalic acid 

Downstream Products

• 90466-78-7 5-acetoxyisophthalic acid 
• 102059-70-1 5-(benzoyloxy)isophthalic acid 
• 137374-13-1 5-acetoxyisophthaloyl acid dichloride 
• 258331-09-8 di-tert-butyl 5-hydroxyisophthalate 
• 224961-40-4 5-hydroxy-1,3-bis[N,N-bis(2-methoxyethyl)]benzenedicarboxamide 
• 252289-76-2 5-acetoxy-1,3-bis[N,N-bis(2-methoxyethyl)]benzenedicarboxamide 
• 258330-87-9 ter(5-hydroxyisophthalic acid)-trimesate 
• 252289-78-4 (3-[3-(3,5-bis-{[bis-(2-methoxy-ethyl)-amino]-methyl}-phenoxymethyl)-5-methylaminomethyl-benzyloxy]-5-{[bis-(2-methoxy-ethyl)-amino]-methyl}-benzyl)-bis-(2-methoxy-ethyl)-amine 
• 224961-41-5 3,5-bis-{3,5-bis-[bis-(2-methoxy-ethyl)-carbamoyl]-phenoxymethyl}-benzoic acid methyl ester 
• 252289-77-3 C₅₀H₇₃N₅O₁₅ 
• 13036-02-7 Dimethyl 5-hydroxyisophthalate 
• 108-95-2 phenol 
• 90844-14-7 dimethyl-5-hydroxyisophthalic acid 
• 23351-91-9 5-bromoisophthalic acid 

Relevant articles and documents

Inclusion complex containing epoxy resin composition for semiconductor encapsulation

The invention is an epoxy resin composition for sealing a semiconductor, including (A) an epoxy resin and (B) a clathrate complex. The clathrate complex is one of (b1) an aromatic carboxylic acid compound, and (b2) at least one imidazole compound represented by formula (II): wherein R2 represents a hydrogen atom, C1-C10 alkyl group, phenyl group, benzyl group or cyanoethyl group, and R3 to R5 represent a hydrogen atom, nitro group, halogen atom, C1-C20 alkyl group, phenyl group, benzyl group, hydroxymethyl group or C1-C20 acyl group. The composition has improved storage stability, retains flowability when sealing, and achieves an effective curing rate applicable for sealing delicate semiconductors.

Naaladase inhibitors for treating retinal disorders and glaucoma

The present invention relates to pharmaceutical compositions and methods for treating a retinal disorder or glaucoma using NAALADase inhibitors.